Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Not Applicable

Recruiting

Conditions: Metastatic Malignant Neoplasm in the Brain
Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Cognitive Assessment
Radiation: Stereotactic Radiosurgery
Radiation: Stereotactic Body Radiation Therapy
Other: Quality-of-Life Assessment

First Posted Date: 2017-06-12

Last Posted Date: 2024-07-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 90

Registration Number: NCT03184038

Locations: 🇺🇸
Jefferson Health New Jersey, Sewell, New Jersey, United States
🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Educational Module and Decision Counseling Program in Increasing Mammography Screening Rates in Formerly Homeless Women With Serious Mental Illness

Not Applicable

Completed

Conditions: Breast - Female

Interventions: Other: Educational Intervention
Other: Counseling
Other: Informational Intervention

First Posted Date: 2017-05-22

Last Posted Date: 2017-05-22

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 23

Registration Number: NCT03162887

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

Early Phase 1

Completed

Conditions: Larynx
Lip, Oral Cavity and Pharynx

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Radiation: Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy
Radiation: Volume Modulated Arc Therapy

First Posted Date: 2017-05-22

Last Posted Date: 2022-11-17

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 24

Registration Number: NCT03162731

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer

Phase 2

Completed

Conditions: Thyroid

Interventions: Other: Radioactive Iodine
Drug: Metformin Hydrochloride
Other: Placebo

First Posted Date: 2017-04-12

Last Posted Date: 2022-12-15

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 13

Registration Number: NCT03109847

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer

Early Phase 1

Completed

Conditions: Larynx
Lip
Oral Cavity
Pharynx

Interventions: Radiation: External Beam Radiation Therapy
Other: Placebo
Drug: Metformin Hydrochloride

First Posted Date: 2017-04-12

Last Posted Date: 2020-12-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 9

Registration Number: NCT03109873

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Pharynx
Larynx
LIP
Oral Cavity

Interventions: Drug: Metformin +Doxycycline
Drug: Metformin Hydrochloride
Drug: Doxycycline

First Posted Date: 2017-03-10

Last Posted Date: 2018-12-24

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 7

Registration Number: NCT03076281

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Phase 1

Completed

Conditions: Prostate Carcinoma Metastatic to the Bone
Stage IV Prostate Adenocarcinoma
Hormone-refractory Prostate Cancer

Interventions: Drug: Niraparib
Radiation: Radium Ra 223 Dichloride

First Posted Date: 2017-03-10

Last Posted Date: 2023-10-10

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT03076203

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Tulane University, New Orleans, Louisiana, United States

and more 3 locations

Genetic Evaluation of Men (GEM)

Terminated

Conditions: Prostate Cancer

Interventions: Other: GEM Registry

First Posted Date: 2017-03-10

Last Posted Date: 2023-12-04

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 595

Registration Number: NCT03076242

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Abington Memorial Hospital, Abington, Pennsylvania, United States

Head and Neck Maskless Immobilization Device in Immobilizing Patients With Head and Neck Cancer or Intracranial Tumors Undergoing Radiation Therapy

Not Applicable

Completed

Conditions: Brain and Nervous System
Intracranial Neoplasm
Head and Neck Cancer

Interventions: Procedure: Computed Tomography
Device: Medical Device
Procedure: Cone-Beam Computed Tomography

First Posted Date: 2017-03-10

Last Posted Date: 2021-09-01

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 12

Registration Number: NCT03076255

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: STAT Inhibitor OPB-111077
Drug: Decitabine
Drug: Venetoclax
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-02-24

Last Posted Date: 2024-03-12

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 37

Registration Number: NCT03063944

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy